{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T20:24:37Z","timestamp":1780777477074,"version":"3.54.1"},"reference-count":30,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:00:00Z","timestamp":1773273600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Summer Undergraduate Research Experience","award":["3480 AM1125"],"award-info":[{"award-number":["3480 AM1125"]}]},{"name":"Pamela Gilligan prize at University College Cork"},{"name":"P. Fitzpatrick Prize in Epidemiology and Public Health Medicine at University College Cork"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Background: Oncology medication costs are increasing internationally; patient attitudes towards these costs remain unclear. Methods: A three-part cross-sectional questionnaire was distributed to patients with breast cancer to determine their attitudes towards oncology medication costs and to explore potential patient-acceptable methods to reduce these costs. Results: A total of 321 patients were eligible for inclusion and 180 fully completed the questionnaire (56.1% response rate). Overall, 67.8% (N = 122\/180) of patients found the costs presented in the questionnaire to be unacceptable. 92.2% (N = 166\/180), 87.8% (N = 158\/180) and 68.9% (N = 124\/180) of participants found the costs of pembrolizumab, palbociclib and trastuzumab respectively to be unacceptable. A total of 72.8% (N = 131\/180) of patients indicated that they would like to be better informed about the societal costs of their cancer treatment and 81.1% (N = 146\/180) of patients believed that reducing the costs of cancer treatment to society is important. There was a statistically significant difference in patient desires to be better informed of societal drug costs between those with early-stage breast cancer and those with metastatic disease (75.8% vs. 47.4%, \u03c72 = 6.923, p = 0.009). Conclusions: These findings indicate that many Irish patients with breast cancer find the societal costs of oncology medications to be unacceptable, and many patients have a desire to be better informed of these costs.<\/jats:p>","DOI":"10.3390\/curroncol33030161","type":"journal-article","created":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T09:23:03Z","timestamp":1773307383000},"page":"161","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Breast Cancer Patient Attitudes Towards Oncology Drug Costs in Ireland"],"prefix":"10.3390","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-2404-2039","authenticated-orcid":false,"given":"Matthew","family":"Cronin","sequence":"first","affiliation":[{"name":"Cancer Research@UCC, University College Cork, T12 CY82 Cork, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9749-3651","authenticated-orcid":false,"given":"Ruth","family":"Kieran","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Cork University Hospital, T12 DC4A Cork, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Steele","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Cork University Hospital, T12 DC4A Cork, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie","family":"Cooke","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Cork University Hospital, T12 DC4A Cork, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2887-7336","authenticated-orcid":false,"given":"Seamus","family":"O\u2019Reilly","sequence":"additional","affiliation":[{"name":"Cancer Research@UCC, University College Cork, T12 CY82 Cork, Ireland"},{"name":"Department of Medical Oncology, Cork University Hospital, T12 DC4A Cork, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,3,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e015700","DOI":"10.1136\/bmjgh-2024-015700","article-title":"Disparities in availability of new cancer drugs worldwide: 1990\u20132022","volume":"9","author":"Li","year":"2024","journal-title":"BMJ Glob. Health"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1001\/jama.2023.25881","article-title":"Analysis of Breast Cancer Mortality in the US\u20141975 to 2019","volume":"331","author":"Sun","year":"2024","journal-title":"JAMA"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41523-025-00768-1","article-title":"Advancing equitable access to innovation in breast cancer","volume":"11","author":"Luis","year":"2025","journal-title":"npj Breast Cancer"},{"key":"ref_4","unstructured":"The IQVIA Institute (2024). The Global Use of Medicines 2024: Outlook to 2028, The IQVIA Institute."},{"key":"ref_5","unstructured":"The IQVIA Institute (2024). Global Oncology Trends 2024: Outlook to 2028, The IQVIA Institute."},{"key":"ref_6","unstructured":"Prior, S., Scott, R., and Walker, E. (2026, March 09). Review of High-Tech Drug Expenditure. Irish Government Economic and Evaluation Service (IGEES), Department of Public Expenditre, Infrastructure, Public Service Reform and Digitalisation, Available online: https:\/\/www.gov.ie\/en\/irish-government-economic-and-evaluation-service-igees\/igees-publication\/review-of-high-tech-drug-expenditure-2021\/."},{"key":"ref_7","unstructured":"Connors, J. (2026, March 09). Health Budget Oversight and Management: Alignment of Health Budget and National Service Plan. Department of Public Expenditure and Reform, Available online: http:\/\/www.budget.gov.ie\/."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Agarwal, A., Livingstone, A., Karikios, D.J., Stockler, M.R., Beale, P.J., and Morton, R.L. (2021). Physician-patient communication of costs and financial burden of cancer and its treatment: A systematic review of clinical guidelines. BMC Cancer, 21.","DOI":"10.1186\/s12885-021-08697-5"},{"key":"ref_9","first-page":"1","article-title":"Pharmaceutical regulation in 15 European countries review","volume":"18","author":"Panteli","year":"2016","journal-title":"Health Syst. Transit."},{"key":"ref_10","unstructured":"Health Service Executive (2026, March 09). Drugs Payment Scheme, Available online: https:\/\/www2.hse.ie\/services\/schemes-allowances\/drugs-payment-scheme\/card\/."},{"key":"ref_11","first-page":"292","article-title":"Willingness to accept chemotherapy and attitudes towards costs of cancer treatment; A multisite survey study in the Netherlands","volume":"74","author":"Zuur","year":"2016","journal-title":"Neth. J. Med."},{"key":"ref_12","first-page":"349","article-title":"New insights into public perceptions of cancer","volume":"7","author":"Geipel","year":"2013","journal-title":"Ecancermedicalscience"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1377\/hlthaff.2011.1300","article-title":"How cancer patients value hope and the implications for cost-effectiveness assessments of high-cost cancer therapies","volume":"31","author":"Lakdawalla","year":"2012","journal-title":"Health Aff."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Krammer, R., and Heinzerling, L. (2014). Therapy preferences in melanoma treatment\u2014Willingness to pay and preference of quality versus length of life of patients, physicians and healthy controls. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0111237"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"6132","DOI":"10.1002\/cam4.3191","article-title":"Therapy preferences in melanoma treatment-Willingness to pay and preference of quality versus length of life of patients, physicians, healthy individuals and physicians with oncological disease","volume":"9","author":"Weiss","year":"2020","journal-title":"Cancer Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"3868","DOI":"10.1200\/JCO.2009.23.1183","article-title":"American Society of Clinical Oncology guidance statement: The cost of cancer care","volume":"27","author":"Meropol","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_17","first-page":"607","article-title":"The utility of cost discussions between patients with cancer and oncologists","volume":"21","author":"Zafar","year":"2015","journal-title":"Am. J. Manag. Care"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.amepre.2020.02.017","article-title":"Patient-Provider Discussions About Out-of-Pocket Costs of Cancer Care in the U.S","volume":"59","author":"Rai","year":"2020","journal-title":"Am. J. Prev. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e1540","DOI":"10.1093\/oncolo\/oyae148","article-title":"National survey of patient perspectives on cost discussions among recipients of copay assistance","volume":"29","author":"Lam","year":"2024","journal-title":"Oncologist"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1634\/theoncologist.2014-0117","article-title":"Patient experience and attitudes toward addressing the cost of breast cancer care","volume":"19","author":"Irwin","year":"2014","journal-title":"Oncologist"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e50","DOI":"10.1200\/JOP.2011.000418","article-title":"Understanding patients\u2019 attitudes toward communication about the cost of cancer care","volume":"8","author":"Bullock","year":"2012","journal-title":"J. Oncol. Pract."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1001\/jamaoncol.2024.5032","article-title":"Advancing Global Pharmacoequity in Oncology","volume":"11","author":"Erfani","year":"2025","journal-title":"JAMA Oncol."},{"key":"ref_23","unstructured":"World Health Organization (2018). Pricing of Cancer Medicines and Its Impacts, World Health Organization."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"104561","DOI":"10.1016\/j.breast.2025.104561","article-title":"Awareness of modifiable lifestyle risk factors and acceptability of secondary risk reduction services amongst Irish breast cancer survivors and oncology healthcare professionals","volume":"84","author":"Steele","year":"2025","journal-title":"Breast"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Kieran, R., Coakley, K., Macanovic, B., Weadick, C., Keogh, R., Cooke, K., Allen, M., Higgins, M., and O\u2019Reilly, S. (Ir. J. Med. Sci., 2025). Cutting waste in cancer care: Acceptability of novel waste-reduction strategies in oral therapies amongst Irish oncology stakeholders, Ir. J. Med. Sci., Epub ahead of printing.","DOI":"10.1007\/s11845-025-04152-7"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1634\/theoncologist.2015-0168","article-title":"Patient Attitudes Regarding the Cost of Illness in Cancer Care","volume":"20","author":"Meisenberg","year":"2015","journal-title":"Oncologist"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1111\/jopy.12112","article-title":"The Stability of Social Desirability: A Latent Change Analysis","volume":"83","author":"Haberecht","year":"2015","journal-title":"J. Pers."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Anderer, S. (JAMA, 2026). Health Care Plan Aims to Lower US Drug Costs and Increase Transparency, JAMA, Epub ahead of printing.","DOI":"10.1001\/jama.2025.26368"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1186\/s12939-024-02262-9","article-title":"Investigating the availability, affordability, and market dynamics of innovative oncology drugs in Morocco: An original report","volume":"23","author":"Benhima","year":"2024","journal-title":"Int. J. Equity Health"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/nrclinonc.2017.31","article-title":"The high price of anticancer drugs: Origins, implications, barriers, solutions","volume":"14","author":"Prasad","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/3\/161\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T10:53:25Z","timestamp":1773312805000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/3\/161"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,12]]},"references-count":30,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["curroncol33030161"],"URL":"https:\/\/doi.org\/10.3390\/curroncol33030161","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,12]]}}}